Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannibinol, cannabidiol and cannabinol

Handbook of Experimental Pharmacology

Volumn 168, Issue , 2005, Pages 657-690

  Huestis, M A ^a  

^a Intramural Research Program   (United States)

Author keywords

Absorption; Alternate matrix; Cannabidiol; Cannabinoids; Distribution; Excretion; Hair; Interpretation; Marijuana; Metabolism; Oral fluid; Pharmacokinetics; Plasma; Sweat; Tetrahydrocannabinol; Urine

Indexed keywords

EID: 85099486162     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-26573-2_23     Document Type: Article

References (150)

1. Adams IB, Martin BR (1996) Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91:1585-1614
2. Agurell S, Leander K (1971) Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 8:391-402
3. Agurell S, Gillespie H, Halldin M, Hollister LE, Johansson E, Lindgren JE, Ohlsson A, Szirmai M, Widman M (1984) A review of recent studies on the pharmacokinetics and metabolism of delta-1-Tetrahydrocannabinol, cannabidiol and cannabinol in man. In: Paton SW, Nahas GG (eds) Marijuana '84. IRL Press, Oxford, pp 49-62
4. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of delta-Tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21-43
5. Atkinson HC, Begg EJ, Darrlow BA (1988) Drugs in human milk clinical pharmacokinetic considerations. Clin Pharmacokinet 14:217-240
6. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992) Marijuana smoking: Effect of varying delta 9-Tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261:114-122
7. Bailey JR, Cunny HC, Paule M, Slikker W Jr (1987) Fetal disposition of delta-9-Tetrahydrocannbinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90:315-321
8. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticityandtremor in amultiple sclerosismodel.Nature 404:84-87
9. Balabanova S, Schneider E (1989) Nachweis von drogen im schweis. Beitr Gerichtl Med 48:45-49
10. Ben-Zvi Z, Burstein S (1974) 7-Oxo-delta-1-Tetrahydrocannabinol: A novel metabolite of delta 1 tetrahydrocannabinol. Int J Clin Pharmacol Ther 8:223-229
11. Ben-Zvi Z, Bergen JR, Burstein S, Sehgal PK, Varanelli C (1976) The metabolism of deltatetrahydrocannabinol in the rhesus monkey. In: Braude MC, Szara S (eds) The pharmacology of marijuana. Raven Press, New York, pp 63-75
12. Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J (1980) Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28:115-117
13. Binitie A (1975) Psychosis following ingestion of hemp in children. Psychopharmacologia 44:301-302
14. Blackard C, Tennes K (1984) Human placental transfer of cannabinoids. N Engl J Med 311:797
15. Blanc JA, Manneh VA, Ernst R, Berger DE, De Keczer SA, Chase C, Centofanti JM, DeLizza AJ (1993) Adsorption losses from urine-bases cannabinoid calibrators during routine use. Clin Chem 39:1705-1717
16. Bloom AS (1982) Effect of delta-9-Tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes. J Pharmacol Exp Ther 221:97-103
17. Bornheim LM, Lasker JM, Raucy JL (1992) Human hepatic microsomal metabolism of delta-1-Tetrahydrocannabinol. Drug Metab Dispos 20:241-246
18. Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta-9-Tetrahydrocannabinol on spasticity: A pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446-452
19. Burstein S, Rosenfeld J, Wittstruck T (1972) Isolation and characterization of two major urinary metabolites of delta-1- Tetrahydrocannabinol. Science 176:422-424
20. Cairns ER, Howard RC, Hung CT, Menkes DB (1990) Saliva THC levels and cannabis intoxication. Report No. 2411, Chemistry Division, Division of Scientific and Industrial Research, LowerHutt, New Zealand, pp 1-71
21. Cairns T, Kippenberger DJ, Scholtz H, Baumgartner WA (1995) determination of carboxy-THC in hair by mass spectrometry/mass spectrometry. In: De Zeeuw RA, Al Hosani I, Al Munthiri S, Maqbool A (eds) Hair Analysis in Forensic Toxicology: Proceedings of the 1995 international conference and workshop. The Organizing Committee of the conference, Abu Dhabi, pp 185-193
22. Cami J, Guerra D, Ugena B, Segura J, De La Torre R (1991) Effect of subject expectancy on the THC intoxication and disposition fromsmoked hashish cigarettes. Pharmacol Biochem Behav 40:115-119
23. Chiang CN, Rapaka RS (1987) Pharmacokinetics and disposition of cannabinoids. In: Rapaka RS, Makriyannis A (eds) NIDA research monograph-structure-Activity relationships of the cannabinoids. National Institute on Drug Abuse, Rockville, pp 173-188
24. Christophersen AS (1986) TetraHydroCannabinol stability in whole blood: Plastic versus glass containers. J Anal Toxicol 10:129-131
25. Cirimele V (1996) Cannabis and amphetamine determination in human hair. In: Kintz P (ed) Drug testing in hair. CRC Press, Boca Raton, pp 181-189
26. Cirimele V, Sachs H, Kintz P, Mangin P (1996) Testing human hair for cannabis. III. Rapid screening procedure for the simultaneous identification of delta9-Tetrahydrocannabinol, cannabinol, and cannabidiol. J Anal Toxicol 20:13-16
27. Claussen U, Korte F (1968)Uber das verhalten von hanf und von delta-9-6a, 10a-Trans-Tetrahydrocannabinol biem rauchen. Justus Liebigs Ann Chem 713:162-165
28. Cone EJ, Lange R, Darwin WD (1998) In vivo adulteration: Excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 22:460-473
29. Dewey WL, McMillan DE, Harris LS, Turk RF (1972) Distribution of radioactivity in brain of tolerant and nontolerant pigeons treated with 3-H-delta-9-Tetrahydrocannabinol. Biochem Pharmacol 22:399-405
30. Ehorn C, Fretthold D, Maharaj M(1994) Ion trap GC/MS/MS for analysis ofTHC fromsweat. Abstract presented at the Society of Forensic Toxicologists annual meeting, Tampa, 31 October-4 November, p 11
31. Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A (1985) Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38:572-578
32. ElSohly HN, Boeren EG, Turner CE, ElSohly MA (1984) Constituents of cannabis sativa L. XXIV: Cannabitetrol, a new polyhydroxylated cannabinoid. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: Chemical, pharmacologic and therapeutic aspects. Academic Press, Orlando, pp 89-96
33. Feng S, ElSohly MA, Salamone S, Salem MY (2000) Simultaneous analysis of delta-9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure. J Anal Toxicol 24:395-402
34. Foltz RL (1984) Analysis of cannabinoids in physiological specimens by gas chromatography/mass spectrometry. In: Baselt RC(ed)Advances in analytical toxicology. Biomedical Publications, Foster City, pp 125-157
35. Garrett ER, Hunt CA (1974) Physiochemical properties, solubility, and protein binding of delta-9-Tetrahydrocannabinol. J Pharm Pharm Sci 63:1056-1064
36. Garrett ER, Hunt CA (1977) Pharmacokinetics of delta-9- Tetrahydrocannabinol in dogs. J Pharm Pharm Sci 66:395-406
37. Gjerde H, Beylich KM, Morland J (1993) Incidence of alcohol and drugs in fatally injured car drivers in Norway. Accid Anal Prev 25:479-483
38. Green MD, Belanger G, Hum DW, Belanger A, Tephly TR (1997) Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein. Drug Metab Dispos 25:1389-1394
39. Greene ML, SaundersDR (1974)Metabolism of tetrahydrocannabinol by the small intestine. Gastroenterology 66:365-372
40. Gross SJ, Soares JR (1978) Validated direct blood delta-9-THC radioimmune quantitation. J Anal Toxicol 2:98-100
41. Gross SJ, Worthy TE, Nerder L, Zimmermann EG, Soares JR, Lomax P (1985) Detection of recent cannabis use by saliva delta-9-THC radioimmunoassay. J Anal Toxicol 9:1-5
42. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360
43. Gustafson RA, Moolchan ET, Barnes A, Levine B, Huestis MA (2003) Validated method for the simultaneous determination of delta-9- Tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 798:145-154
44. Guy GW, Robson PJ (2004a) A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther 3:121-152
45. Guy GW, Robson PJ (2004b) A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics ofCBMEper oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 3:79-120
46. Hall BJ, Satterfield-Doerr M, Parikh AR, Brodbelt JS (1998) Determination of cannabinoids in water and human saliva by solid-phase microextraction and quadrupole ion trap gas chromatography-mass spectrometry. Anal Chem 70:1788-1796
47. Halldin MM, Widman M, Bahr CV, Lindgren JE, Martin BR (1982) Identification of in vitro metabolites of delta-Tetrahydrocannabinol formed by human livers. DrugMetab Dispos 10:297-301
48. Hampson AJ, Grimaldi M, Axelrod J, Wink D(1998) Cannabidiol and (-) delta-9-Tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95:8268-8273
49. Hanson VW, Buonarati MH, Baselt RC, Wade NA, Yep C, Biasotti AA, Reeve VC, Wong AS, Orbanowsky MW(1983) Comparison of 3H-And 125I-radioimmunoassay and gas chromatography/mass spectrometry for the determination of delta-9-Tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol 7:96-102
50. Harder S, Rietbrock S (1997) Concentration-effect relationship of delta-9-Tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 35:155-159
51. Harvey DJ (2001) Absorption, distribution, and biotransformation of the cannabinoids. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S (eds) Marijuana and medicine. Humana Press, Totowa, pp 91-103
52. Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303-320
53. Harvey DJ, Paton WDM (1986) Metabolism of the cannabinoids. Rev Biochem Toxicol 6:221-264
54. Harvey DJ, Martin BR, Paton WDM(1979) Identification and measurement of cannabinoids and their in vivo metabolites in liver by gas chromatography-mass spectrometry. In: Nahas GG, Paton WDM (eds) Marijuana: Biological effects. Pergamon Press, Oxford, pp 45-62
55. Hawks RL (1982) The constituents of cannabis and the disposition and metabolism of cannabinoids. In: Hawks R (ed) The analysis of cannabinoids in biological Fluids. Research Monograph 42. National Institute on Drug Abuse, Rockville, pp 125-137
56. Hawks RL (1983) Developments in cannabinoid analyses of body fluids: Implications for forensic applications. In: Agurell S, Dewey W, Willette R (eds) The cannabinoids: Chemical, pharmacologic, and therapeutic aspects. Academic Press, Rockville, pp 1-12
57. Heishman SJ, Stitzer ML, Yingling JE (1989) Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 34:173-179
58. Holdcroft A (1984) Pain therapy. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 181-186
59. Huang W, Moody DE, Andrenyak DM, Smith EK, Foltz RL, Huestis MA, Newton JF (2001) Simultaneous determination of delta-9-Tetrahydrocannabinol and 11-nor-9-carboxydelta-9-Tetrahydrocannabinol in human plasma by solid phase extraction and gas chromatography-negative ionchemical ionization- massspectrometry. J AnalToxicol 25:531-537
60. Huestis MA, Cone EJ (1998a) Alternative testing matrices. In: Karch SB (ed) Drug abuse handbook. CRC Press, Boca Raton, pp 799-857
61. Huestis MA, Cone EJ (1998b) Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22:445-454
62. Huestis MA, Cone EJ (2004) Relationship of Delta-9-Tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 28:394-399
63. Huestis MA, Dickerson S, Cone EJ (1992a) Can saliva THC levels be correlated to behavior? American Academy of Forensic Sciences Annual Meeting, New Orleans, p 190
64. Huestis MA, Henningfield JE, Cone EJ (1992b) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276-282
65. Huestis MA, Henningfield JE, Cone EJ (1992c) Blood cannabinoids. II.Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-Tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta- 9-Tetrahydrocannabinol (THCCOOH). J Anal Toxicol 16:283-290
66. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992d) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52:31-41
67. Huestis MA, Mitchell JM, Cone EJ (1995) Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 19:443-449
68. Huestis MA, Mitchell JM, Cone EJ (1996) Urinary excretion profiles of 11-nor-9-carboxy-Δ9-Tetra Hydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 20:441-452
69. Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215:35-44
70. Hunt CA, Jones RT, Herning RI, Bachman J (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9:245-260
71. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365-373
72. Jehanli A, Brannan S, Moore L, Spiehler VR (2001) Blind trials of an onsite saliva drug test for marijuana and opiates. J Forensic Sci 46:1214-1220
73. Joern WA (1992) Surface adsorption of the urinary marijuana carboxy metabolite: The problem and a partial solution. J Anal Toxicol 16:401
74. Johansson E, Halldin MM(1989)Urinary excretion half-life of delta1-Tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13:218-223
75. Johansson E, Agurell S, Hollister LE, Halldin MM (1988) Prolonged apparent half-life of delta-1-Tetrahydrocannabinol in plasma of chronic marijuana users. J PharmPharmacol 40:374-375
76. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989a) Terminal elimination plasma half-life of delta-1-Tetrahydrocannabinol (selta-1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 37:273-277
77. Johansson E, Noren K, Sjovall J, Halldin MM (1989b) Determination of delta-1-Tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3:35-38
78. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. J Am Med Assoc 290:1757-1762
79. Kelly P, Jones RT (1992) Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16:228-235
80. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995a) Cannabinoids in humans. I. Analysis of delta-9-Tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 19:285-291
81. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, Nixon FE, Fitzgerald MJ, Reeves RR, Wood MJ (1995b) Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 19:292-298
82. Kidwell DA, Holland JC, Athanaselis S (1998) Testing for drugs of abuse in saliva and sweat. J Chromatogr 713:111-135
83. Kim KR, Yoon HR (1996) Rapid screening for acidic non-steroidal anti-inflammatory drugs in urine by gas chromatography-mass spectrometry in the selected-ion monitoring mode. J Chromatogr B Biomed Appl 682:55-66
84. Kintz P, Cirimele V, Mangin P (1995) Testing human hair for cannabis II. Identification of THC-COOH by GC-MS-NCI as a unique proof. J Forensic Sci 40:619-622
85. Kintz P, Brenniesen R, Bundeli P, Mangin P (1997) Sweat testing for heroin and metabolites in a heroin maintenance program. Clin Chem 43:736-739
86. Kintz P, Cirimele V, Ludes B (2000) Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 24:557-561
87. Kreuz DS, Axelrod J (1973) Delta-9-Tetrahydrocannabinol: Localization in body fat. Science 179:391-393
88. Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144-160
89. Law B, Mason PA, Moffat AC, Gleadle RI, King LJ (1984) Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36:289-294
90. Lee CC, Chiang CN (1985) Appendix. Maternal-fetal transfer of abused substances: Pharmacokinetic and pharmacodynamic data. In: Chiang CN, Lee CC (eds) NIDA Research monograph 60. U.S. Department of Health and Human Services, Rockville, pp 110-147
91. Lemberger L, Silberstein SD, AxelrodJ, Kopin IJ (1970)Marihuana: Studies onthe disposition and metabolism of delta-9-Tetrahydrocannabinol in man. Science 170:1320-1322
92. Lemberger L, Tamarkin NR, Axelrod J (1971) Delta-9-Tetrahydrocannabinol: Metabolism and disposition in long-Term marihuana smokers. Science 173:72-74
93. Lemberger L, Crabtree RE, Rowe HM (1972) 11-hydroxy-delta-9- Tetrahydrocannabinol: Pharmacology, disposition, and metabolism of a major metabolite of marijuana in man. Science 177:62-64
94. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H (1981) Clinical effects and plasma levels of delta-9-Tetrahydrocannabinol (delta-9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 74:208-212
95. Malfait AM, Galllily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, FeldmannM (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-Arthritic therapeutic inmurine collagen-induced arthritis. ProcNatlAcad SciUSA97:9561-9566
96. Manno JE, Ferslew KE, Manno BR (1984) Urine excretion patterns of cannabinoids and the clinical application of the EMIT-d.a.u. cannabinoid urine assay for substance abuse treatment. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: Chemical, pharmacologic, and therapeutic aspects. Harcourt Brace Jonanovich, Orlando, pp 281-290
97. Manno JE, Manno BR, Kemp PM, Alford DD, Abukhalaf IK, McWilliamsME, Hagaman FN, Fitzgerald MJ(2001)Temporal indicationofmarijuanause canbe estimated fromplasma and urine concentrations of delta-9-Tetrahydrocannabinol, 11-hydroxy-delta-9-Tetrahydrocannabinol, and 11-nor-delta-9- Tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25:538-549
98. Martin BR, Dewey WL, Harris LS, Beckner JS (1977) 3H-Delta-9- Tetrahydrocannbinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 17:457-470
99. Mason AP, McBay AJ (1984) Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashers in North Carolina, 1978-1981. J Forensic Sci 29:987-1026
100. Mason AP, McBay AJ (1985) Cannabis: Pharmacology andinterpretationof effects. J Forensic Sci 30:615-631
101. Matsunaga T, Iwawaki Y, Watanabe K, Yamamoto I, Kageyama T, Yoshimura H (1995) Metabolism of delta-9-Tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 56:2089-2095
102. Mattes RD, Shaw LM, Edling-Owens J, Engelman K, ElSohly MA (1993) Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 44:745-747
103. Mattes RD, Engelman K, Shaw LM, ElSohly MA (1994) Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49:187-195
104. McArdle K, Mackie P, Pertwee R, Guy G, WhittleB, Hawksworth G(2001) Selective inhibition of delta-9-Tetrahydrocannabinol metabolite formation by cannabidiol in vitro (abstract) in Proceedings of the BTS Annual Congress. Toxicology 168:133-134
105. McBurney LJ, Bobbie BA, Sepp LA (1986) GC/MS and Emit analyses for delta-9-Tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 10:56-64
106. Mechoulam R (1970) Marihuana chemistry. Science 168:1159-1166
107. Mechoulam R, Zvi ZB, Agurell S, Nilsson IM, Nilsson JLG, Edery H, Grunfeld Y (1973) Delta-6 tetrahydrocannabinol-7-oic acid, a urinary delta-6-THC metabolite: Isolation and synthesis. Experientia 29:1193-1195
108. Meier HJ, Vonesch HJ(1997)Cannabis-intoxikationnach salatgenuss. SchweizMedWochenschr 127:214-218
109. Melamede R (1984) Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 111-122
110. Moeller MR, Doerr G, Warth S (1992) Simultaneous quantitation of delta-9-Tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9- Tetrahydrocannabinol (THC-COOH) in serumby GC/MS using deuterated internal standards and its application to a smoking study and forensic cases. J Forensic Sci 37:969-983
111. Moore C, Guzaldo F, Donahue T (2001) The determination of 11-nor-delta-9-Tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatography-mass spectrometry and high-volume injection. J Anal Toxicol 25:555-558
112. Mura P, Kintz P, Papet Y, Ruesch G, Piriou A (1999) Evaluation of six rapid tests for screening of cannabinoids in sweat, saliva and urine. Acta Clin Belg 1:35-38
113. Nebro W, Barnes A, Gustafson R, Moolchan E, Huestis M (2004) Delta-9-Tetrahydrocannabinol (THC), 11-hydroxy-delta-9-Tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-delta-9-Tetrahydrocannabinol (THCCOOH) in human plasma following oral administration of hemp oil. 2004 FBI/SOFT/TIAFT Meeting
114. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J (2001) Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 25:289-303
115. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK(1980) Plasma delta-9-Tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409-416
116. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1981) Plasma levels of delta-9-Tetrahydrocannabinol after intravenous, oral and smoke administration. NIDA Res Monogr 34:250-256
117. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1982) Single dose kinetics of deuteriumlabelled delta-1-Tetrahydrocannabinol in heavy and light cannabis users. Biomed Environ Mass Spectrom 9:6-10
118. Ohlsson A, Agurell S, Londgren JE, Gillespie HK, Hollister LE (1985) Pharmacokinetic studies of delta-1-Tetrahydrocannabinol in man. In: Barnett G, Chiang CN (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs.MosbyYearbook, St Louis, pp 75-92
119. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Singledose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77-83
120. Owens SM, McBay AJ, Reisner HM, Perez-Reyes M (1981) 125 l radioimmunoassay of delta-9-Tetrahydrocannabinol in blood and plasma with a solid-phase second-Antibody separation method. Clin Chem 27:619-624
121. Peat MA (1989) Distribution of delta-9-Tetrahydrocannabinol and its metabolites. In: Baselt RC (ed) Advances in analytical toxicology II. Year Book Medical Publishers, Chicago, pp 186-217
122. Peel HW, Perrigo BJ, Mikhael NZ (1984) Detection of drugs in saliva of impaired drivers. J Forensic Sci 29:185-189
123. Perez-Reyes M (1985) Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chiang CN (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Biomedical Publications, Foster City, pp 287-310
124. Perez-Reyes M(1990)Marijuana smoking: Factors that influence the bioavailability of tetrahydrocannabinol. In: Chiang CN, Hawks RL (eds) Research findings on smoking of abused substances. NIDA Research Monograph 99, Rockville, pp 42-62
125. Perez-Reyes M, Wall ME (1982) Presence of delta-9-Tetrahydrocannabinol in human milk. N Engl J Med 307:819-820
126. Perez-Reyes M, Timmons MC, Lipton MA, Davis KH, Wall ME (1972) Intravenous injection in man of delta-9-Tetrahydrocannabinol and 11-OH-delta-9-Tetrahydrocannabinol. Science 177:633-635
127. Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, Davis KH (1973a) Pharmacology of orally administered delta-9-Tetrahydrocannabinol. Clin Pharmacol Ther 14:48-55
128. Perez-Reyes M, Timmons MC, Davis KH, Wall EM (1973b) A comparison of the pharmacological activity in man of intravenously administered delta-9-Tetrahydrocannabinol, cannabinol and cannabidiol. Experientia 29:1368-1369
129. Perez-Reyes M, Owens SM, Di Guiseppi S (1981) The clinical pharmacology and dynamics of marijuana cigarette smoking. J Clin Pharmacol 21:201S-207S
130. Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE (1982) Comparison of effects of marijuana cigarettes of three different potencies. Clin Pharmacol Ther 31:617-624
131. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic/Plenum Publishers, New York, pp 32-83
132. Plasse T (1984) Antiemetic effects of cannabinoids. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 165-180
133. Samyn N, vanHaeren C (2000) On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med 113:150-154
134. Shaw LM, Edling-Owens J, Mattes R (1991) Ultrasensitive measurement of delta-9-Tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. Clin Chem 37:2062-2068
135. Soares JR, Gross SJ (1976) Separate radioimmune measurements of body fluid delta-9THC and 11-nor-9-carboxy-delta-THC. Life Sci 19:1711-1717
136. Soares JR, Grant JD, Gross SJ (1982) Significant developments in radioimmune methods applied to delta-9-THC and its 9-substituted metabolites. In:Hawks R (ed) NIDA Research Monograph 42: National Institute on Drug Abuse, Bethesda, pp 44-55
137. Sporkert F, Pragst F, Ploner CJ, Tschirch A, Stadelmann AM (2001) Pharmacokinetic investigations and delta-9-Tetrahydrocannabinol and its metabolites after single administration of 10 mg Marinol in attendance of a psychiatric study. The Annual Meeting of The International Association of Forensic Toxicologists, Prague, pp 1-62
138. Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004) Human skin permeation of delta-8-Tetrahydrocannabinol, cannabidiol and cannabinol. J PharmPharmacol 56:291-297
139. Turner CE, ElSohly MA, Boeren EG (1980) Constituents of cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169-234
140. Vaughan CW, Christie MJ (1984) Mechanisms of cannabinoid analgesia. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 89-100
141. Wall ME, Perez-Reyes M(1981) The metabolism of delta-9- Tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178S-189S
142. Wall ME, Taylor HL (1984) Conjugation of acidic metabolites of delta-8 and delta-9-THC in man. In:Harvey DJ, Paton SW, Nahas GG (eds)Marihuana 84 Proceedings of the Oxford Symposium on Cannabis. IRL Press Limited, Oxford, pp 69-76
143. Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude MC, Szara S (eds) The Pharmacology of marihuana. Raven Press, New York, pp 93-113
144. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of delta-9-Tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352-363
145. Watanabe K, Tanaka T, Yamamoto I, Yoshimura H (1988) Brain microsomal oxidation of delta-8-And delta-9-Tetrahydrocannabinol. Biochem Biophys Res Commun 157:75-80
146. Widman M, Agurell S, Ehrnebo M, Jones G (1974) Binding of (+) and (-)-delta1-Tetrahydrocannabinols and (-)-7-hydroxy-delta1-Tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol 26:914-916
147. Widman M, Nordqvist M, Dollery CT, Briant RH (1975) Metabolism of delta-1-Tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism. J Pharm Pharmacol 27:842-848
148. Williams PL, Moffat AC (1980) Identification in human urine of delta-9-Tetrahydrocannabinol-11-oic glucuronide: A tetrahydrocannabinol metabolite. J PharmPharmacol 32:445-448
149. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362:1517-1526
150. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982)Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology (Berl) 76:245-250